Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease

Kidney International

Volumn 65, Issue 3, 2004, Pages 1009-1016

  Oberg, B Payson ^b   McMenamin, Elizabeth ^b   Lucas, F Lee ^b   McMonagle, Ellen ^b   Morrow, Jason ^b   Ikizler, T Alp ^b   Himmelfarb, Jonathan ^a  

^a MAINE MEDICAL CENTER   (United States)

^b NONE

Author keywords

Carbonyl; Chronic kidney disease; Inflammation; Oxidant stress; Thiols

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CARBONYL DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; ISOPROSTANE DERIVATIVE; THIOL DERIVATIVE;

ACUTE DISEASE; ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIETARY INTAKE; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; NEPHRITIS; OXIDATIVE STRESS; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

EID: 1342322653     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2004.00465.x     Document Type: Article

References (54)

1. CORESH J, ASTOR BC, GREEN T, et al: Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 41:1-12, 2003
2. MCCLELLAN WM, KNIGHT DF, KARP H, BROWN WW: Early detection and treatment of renal disease in hospitalized diabetic and hypertensive patients: Important differences between practice and published guidelines. Am J Kidney Dis 29:368-375, 1997
3. KAUSZ AT, KHAN SS, ABICHANDANI R, et al: Management of patients with chronic renal insufficiency in the northeastern United States. J Am Soc Nephrol 12:1501-1507, 2001
4. CORESH J, WEI GL, MCQUILLAN G, et al: Prevalence of high blood pressure and elevated serum creatinine level in the United States: Findings from the Third National Health and Nutrition Examination Survey (1988-1994). Arch Int Med 161:1207-1216, 2001
5. NATIONAL KIDNEY FOUNDATION: Clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification [abstract]. Am J Kidney Dis 39:S1-S266, 2002
6. CLINICAL PRACTICE GUIDELINES FOR CHRONIC KIDNEY DISEASE: Evaluation, classification, and stratification. Am J Kidney Dis 39:S17-S31, 2002
7. SHLIPAK MG, SIMON JA, GRADY D, et al: Renal insufficiency and cardiovascular events in post-menopausal women with coronary heart disease. J Am Coll Cardiol 38:705-711, 2001
8. MANN JF, GERSTEIN HC, POGUE J, et al: Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: The HOPE randomized trial. Ann Int Med 134:629-636, 2001
9. DRIES DL, EXNER DV, DOMANSKI MJ, el al: The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventrical systolic dysfunction [abstract]. J Am Coll Cardiol 35:681-689, 2002
10. MCCULLOUGH PA, SOMAN SS, SHAH SS, et al: Risks associated with renal dysfunction in patients in the coronary care unit [abstract]. J Am Coll Cardiol 36:679-684, 2000
11. MATTS JP, KARNEGIS JN, CAMPOS CT, et al: Serum creatinine as an independent predictor of coronary heart disease mortality in normotensive survivors of myocardial infarction [abstract]. J Fam Practice 36:497-503, 1993
12. MUNTNER P, JIANG H, HAMM L, et al: Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol 13:745-753, 2002
13. MANJUNATH G, TIGHIOUART H, CORESH J, et al: Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney Int 63:1121-1129, 2003
14. STENVINKEL P, HEIMBURGER O, PAULTRE F, et al: Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 51:1899-1911, 1999
15. ARICI M, WALLS J: End-stage renal disease, atherosclerosis, and cardiovascular mortality: Is C-reactive protein the missing link? Kidney Int 59:407-414, 2001
16. STENVINKEL P: Inflammatory and atherosclerotic interactions in the depleted uremic patient. Blood Purif 10:53-61, 2001
17. HIMMELFARB J, IKIZLER TA, STENVINKEL P, HAKIM RM: The elephant in uremia: Reflections on oxidant stress as a unifying concept. Kidney Int 62:1524-1538, 2002
18. LEVEY AS, BOSCH JP, LEWIS JB, et al: A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Int Med 130:461-470, 1999
19. ELLMAN GL: Tissue sulfhydryl groups. Archives of Biochemistry and Biophysics 82:70-77, 1959
20. HU ML, LOUIE S, CROSS CE, et al: Antioxidant protection against hypochlorous acid in human plasma. J Lab Clin Med 121:257-262, 1993
21. HIMMELFARB J, MCMONAGLE E, MCMENAMIN E: Plasma protein thiol oxidation and carbonyl formation in chronic renal failure. Kidney Int 58:2571-2578, 2000
22. BUSS H, CHAN TP, SLUIS KB, et al: Protein carbonyl measurement by a sensitive ELISA method. Free Radical Biology & Medicine 23:361-366, 1997
23. WINTERBOURN CC, BUSS IH: Protein carbonyl measurement by enzyme-linked immunosorbent assay. Methods in Enzymology 300:106-111, 1999
24. MORROW JD, CHEN Y, BRAME CJ, et al: The isoprostanes: Unique prostaglandin-like products of free-radical-initiated lipid peroxidation. Drug Metab Rev 31:117-139, 1999
25. VANHOLDER R, ARGILES A, BAURMEISTER U, et al: Uremic toxicity: Present state of the art. Int J Artif Organs 24:695-725, 2001
26. DUBOURG L, MICHOUDET C, COCHAT P, BAVEREL G: Human kidney tubules detoxify chloroacetaldehyde, a presumed nephrotoxic metabolite of ifosfamide. J Am Soc Nephrol 12:1615-1623, 2001
27. MICHOUDET C, BAVEREL G: Metabolism of acetaldehyde in human and baboon renal cortex. FEBS Lett 216:113-117, 1987
28. SILBERNAGL S, DEETJEN P: The tubular reabsorption of L-cystine and L-cysteine: A common transport system with L-arginine or not? Pflugers Arch 337:227-284, 1972
29. HEUNER A, AZAR C, MILDENBERGER S, SILBERNAGL S: Renal handling of glutathione. Contr Nephrol 63:49-52, 1988
30. VÖLKL H, SILBERNAGL S: Reexamination of the interplay between dibasic amino acids and L-cystine/L-cysteine during tubular reabsorption. Pflugers Arch 395:196-200, 1982
31. STUVELING EM, HILLEGE HL, BAKKER SJ, et al: C-reactive protein is associated with renal function abnormalities in a non-diabetic population. Kidney Int 63:654-661, 2003
32. PECOITS-FILHO R, HEIMBURGER O, BARANY P, et al: Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis 41:1212-1218, 2003
33. PANICHI V, MIGLIORI M, DE PIETRO S, et al: C-reactive protein and interleukin-6 levels are related to renal function in predialytic chronic renal failure. Nephron 91:594-600, 2002
34. DESCAMPS-LATSCHA B, HERBELIN A, NGUYEN AT, et al: Balance between IL-1 beta, TNF-alpha, and their specific inhibitors in chronic renal failure and maintenance dialysis. Relationships with activation markers of T cells, B cells, and monocytes. J Immunol 154:882-892, 1995
35. SHLIPAK MG, FRIED LF, CRUMP C, et al: Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation 107:87-92, 2003
36. SARNAK MJ, POINDEXTER A, WANG SR, et al: Serum C-reactive protein and leptin as predictors of kidney disease progression in the Modification of Diet in Renal Disease Study. Kidney Int 62:2208-2215, 2002
37. DAVIES MJ, FU S, WANG H, DEAN RT: Stable markers of oxidant damage to proteins and their application in the study of human disease. Free Rad Biol Med 27:1151-1163, 1999
38. UCHIDA K: Role of reactive aldehyde in cardiovascular diseases. Free Rad Biol Med 28:1685-1696, 2000
39. MIYATA T, UEDA Y, IZUHARA Y, et al: Accumulation of carbonyls accelerates the formation of pentosidine, an advanced glycation end product: Carbonyl stress in uremia. J Am Soc Nephrol 9:2349-2356, 1998
40. HANDELMAN GJ, WALTER MF, ADHIKARLA R, et al: Elevated plasma F2-isoprostanes in patients on long-term hemodialysis. Kidney Int 51:1960-1966, 2001
41. IKIZLER TA, MORROW JD, ROBERTS LJ, et al: Plasma F2 isoprostane levels are elevated in chronic hemodialysis patients. Clin Nephrol 88:190-197, 2002
42. ANNUK M, ZILMER M, LIND L, et al: Oxidative stress and endothelial function in chronic renal failure. J Am Soc Nephrol 12:2747-2752, 2001
43. BOLTON CH, DOWNS LG, VICTORY JGG, et al: Endothelial dysfunction in chronic renal failure: Roles of lipoprotein oxidation and pro-inflammatory cytokines. Nephrol Dial Transplant 16:1189-1197, 2001
44. MEZZANO D, PAIS EO, ARANDA E, et al: Inflammation, not hyperhomocysteinemia, is related to oxidative stress and hemostatic and endothelial dysfunction in uremia. Kidney Int 60:1844-1850, 2001
45. WITKO-SARSAT V, FRIEDLANDER M, NGUYEN-KHOA T, et al: Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 161:2524-2532, 1998
46. GRIENDLING KK, MINIERI CA, OLLERENSHAW JD, ALEXANDER RW: Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 74:1141-1148, 1994
47. WINGLER K, WÜNSCH S, KREUTZ R, et al: Upregulation of the vascular NAD(P)H-oxidase isoforms NOX1 and NOX4 by the renin-angiotensin system in vitro and in vivo. Free Rad Biol Med 31:1456-1464, 2001
48. DENG G, VAZIRI ND, JABBARI B, et al: Increased tyrosine nitration of the brain in chronic renal insufficiency: Reversal of antioxidant therapy and angiotensin-converting enzyme inhibition. J Am Soc Nephrol 12:1892-1899, 2001
49. KB. J Lab Clin Med 140:103-109, 2002
50. MIYATA T, VAN YPERSELE DE STRIHOU C, UEDA Y, et al: Angiogensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: Biochemical mechanisms. J Am Soc Nephrol 13:2478-2487, 2002
51. STENVINKEL P, ANDERSSON P, WANG T, et al: Do ACE-inhibitors suppress tumour necrosis factor-alpha production in advanced chronic renal failure? J Intern Med 246:503-507, 1999
52. RIDKER PM, RIFAI N, PFEFFER MA, et al: Long-term effects of Pravastatin on plasma concentration of C-reactive protein. Circulation 100:230-235, 1999
53. RIDKER PM, RIFAI N, PFEFFER MA, et al: Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 98:839-844, 1998
54. RIDKER PM, RIFAI N, CLEARFIELD M, et al: Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 344:1959-1965, 2001